CA2181033C - Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections - Google Patents
Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections Download PDFInfo
- Publication number
- CA2181033C CA2181033C CA002181033A CA2181033A CA2181033C CA 2181033 C CA2181033 C CA 2181033C CA 002181033 A CA002181033 A CA 002181033A CA 2181033 A CA2181033 A CA 2181033A CA 2181033 C CA2181033 C CA 2181033C
- Authority
- CA
- Canada
- Prior art keywords
- hbv
- nbdnj
- cells
- virus
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002672 hepatitis B Diseases 0.000 title claims description 7
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 title description 3
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 89
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 229960002920 sorbitol Drugs 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 230000028327 secretion Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 68
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 64
- 229960001512 miglustat Drugs 0.000 description 61
- 239000002609 medium Substances 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 32
- 210000002845 virion Anatomy 0.000 description 32
- 241000700605 Viruses Species 0.000 description 23
- 239000002245 particle Substances 0.000 description 16
- 101710084021 Large envelope protein Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 108020005202 Viral DNA Proteins 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
- 238000000326 densiometry Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 6
- 101710091045 Envelope protein Proteins 0.000 description 6
- 241000711466 Murine hepatitis virus Species 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000724709 Hepatitis delta virus Species 0.000 description 5
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 5
- 238000000211 autoradiogram Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 208000029570 hepatitis D virus infection Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940124884 Engerix-B Drugs 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 241000285366 HBV genotype D Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 101150098499 III gene Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 1
- AAKDPDFZMNYDLR-XZBKPIIZSA-N N-methyl-1-deoxynojirimycin Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101100381937 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) bprA gene Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000890661 Sudra Species 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950008802 fialuridine Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HMUWJRKMCCROKD-UHFFFAOYSA-M sodium;4-hexadecan-8-ylbenzenesulfonate Chemical compound [Na+].CCCCCCCCC(CCCCCCC)C1=CC=C(S([O-])(=O)=O)C=C1 HMUWJRKMCCROKD-UHFFFAOYSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000007181 unidentified human coronavirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18151994A | 1994-01-13 | 1994-01-13 | |
US08/181,519 | 1994-01-13 | ||
PCT/US1994/014548 WO1995019172A1 (en) | 1994-01-13 | 1994-12-23 | Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2181033A1 CA2181033A1 (en) | 1995-07-20 |
CA2181033C true CA2181033C (en) | 2007-09-04 |
Family
ID=22664619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002181033A Expired - Lifetime CA2181033C (en) | 1994-01-13 | 1994-12-23 | Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections |
Country Status (14)
Country | Link |
---|---|
US (1) | US6037351A (el) |
EP (1) | EP0739205B1 (el) |
JP (1) | JP3628021B2 (el) |
KR (1) | KR100348657B1 (el) |
CN (1) | CN1074921C (el) |
AT (1) | ATE186836T1 (el) |
AU (1) | AU1403795A (el) |
CA (1) | CA2181033C (el) |
DE (1) | DE69421828T2 (el) |
DK (1) | DK0739205T3 (el) |
ES (1) | ES2140652T3 (el) |
GR (1) | GR3032527T3 (el) |
PT (1) | PT739205E (el) |
WO (1) | WO1995019172A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030100532A1 (en) | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
CA2309321A1 (en) | 1997-11-10 | 1999-05-20 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
AU762125B2 (en) | 1998-02-12 | 2003-06-19 | G.D. Searle & Co. | Use of (N)-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
EP1714676A3 (en) * | 1998-02-12 | 2006-11-15 | G.D. Searle LLC. | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
EP1658846B1 (en) * | 1999-02-12 | 2008-07-30 | United Therapeutics Corporation | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections |
WO2001008672A2 (en) * | 1999-02-12 | 2001-02-08 | G.D. Searle & Co. | Glucamine compounds for treating hepatitis virus infections |
AU3595500A (en) | 1999-02-12 | 2000-08-29 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
ATE382351T1 (de) | 1999-08-10 | 2008-01-15 | Univ Oxford | Langkettige n-alkyl verbindungen und deren oxa- derivate zur verwendung als anitvirale mittel |
EP1261339A1 (en) * | 2000-02-14 | 2002-12-04 | Pharmacia Corporation | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
CA2576425A1 (en) * | 2004-08-13 | 2006-08-17 | Migenix Inc. | Compositions and methods for treating or preventing hepadnaviridae infection |
EP2023927B1 (en) | 2006-05-24 | 2015-02-25 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
JP2010510171A (ja) * | 2006-08-21 | 2010-04-02 | ユナイテッド セラピューティクス コーポレーション | ウイルス感染症の治療のための併用療法 |
US8097728B2 (en) | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
JP2013233113A (ja) * | 2012-05-09 | 2013-11-21 | Osaka Univ | 物理的負荷への耐性が向上した細胞の製造方法 |
RU2743694C1 (ru) * | 2019-12-04 | 2021-02-24 | Общество с ограниченной ответственностью "29 февраля" | Миглустат N-бутил-1,5-дидезокси-1,5-имино-D-глюцит |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1555654A (en) * | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
US4849430A (en) * | 1988-03-09 | 1989-07-18 | Monsanto Company | Method of inhibiting virus |
US4957926A (en) * | 1988-12-22 | 1990-09-18 | Monsanto Company | Method of treating herpesviruses |
US5030638A (en) * | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
-
1994
- 1994-12-23 AU AU14037/95A patent/AU1403795A/en not_active Abandoned
- 1994-12-23 CN CN94195049A patent/CN1074921C/zh not_active Expired - Lifetime
- 1994-12-23 KR KR1019960703780A patent/KR100348657B1/ko not_active IP Right Cessation
- 1994-12-23 DE DE69421828T patent/DE69421828T2/de not_active Expired - Lifetime
- 1994-12-23 AT AT95905416T patent/ATE186836T1/de active
- 1994-12-23 PT PT95905416T patent/PT739205E/pt unknown
- 1994-12-23 DK DK95905416T patent/DK0739205T3/da active
- 1994-12-23 WO PCT/US1994/014548 patent/WO1995019172A1/en active IP Right Grant
- 1994-12-23 JP JP51902495A patent/JP3628021B2/ja not_active Expired - Fee Related
- 1994-12-23 ES ES95905416T patent/ES2140652T3/es not_active Expired - Lifetime
- 1994-12-23 US US08/676,153 patent/US6037351A/en not_active Expired - Lifetime
- 1994-12-23 EP EP95905416A patent/EP0739205B1/en not_active Expired - Lifetime
- 1994-12-23 CA CA002181033A patent/CA2181033C/en not_active Expired - Lifetime
-
2000
- 2000-01-31 GR GR20000400223T patent/GR3032527T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1149253A (zh) | 1997-05-07 |
DK0739205T3 (da) | 2000-05-01 |
ATE186836T1 (de) | 1999-12-15 |
EP0739205B1 (en) | 1999-11-24 |
WO1995019172A1 (en) | 1995-07-20 |
DE69421828D1 (de) | 1999-12-30 |
CA2181033A1 (en) | 1995-07-20 |
GR3032527T3 (en) | 2000-05-31 |
PT739205E (pt) | 2000-04-28 |
CN1074921C (zh) | 2001-11-21 |
EP0739205A1 (en) | 1996-10-30 |
JP3628021B2 (ja) | 2005-03-09 |
JPH09508111A (ja) | 1997-08-19 |
KR100348657B1 (ko) | 2003-08-02 |
AU1403795A (en) | 1995-08-01 |
DE69421828T2 (de) | 2000-04-20 |
US6037351A (en) | 2000-03-14 |
ES2140652T3 (es) | 2000-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2181033C (en) | Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections | |
Block et al. | Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. | |
US6465487B1 (en) | Inhibition of membrane-associated viral replication | |
US6465488B1 (en) | Inhibition of glycolipid biosynthesis | |
US7816560B1 (en) | Long chain n-alkyl compounds and oxa-derivatives thereof | |
Mehta et al. | Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications | |
JPH085804B2 (ja) | A型及びb型肝炎混合アジュバントワクチン | |
JP2005508848A (ja) | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 | |
Block et al. | Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs | |
JP2005508848A6 (ja) | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 | |
WO2001001978A1 (fr) | Compositions de medicaments servant a prevenir ou a traiter la myocardite virale | |
KR101755133B1 (ko) | 이미노슈가 및 바이러스성 질환을 치료하는 방법 | |
KR910010020B1 (ko) | 항바이러스제 | |
KR20220018552A (ko) | 항 간염 바이러스 의약품 제조를 위한 암렉사녹스의 용도 | |
US20050053625A1 (en) | Method of treating viral infections | |
BLOCK et al. | Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation) | |
CN114025751A (zh) | 用于治疗乙型肝炎病毒感染的组合物和方法 | |
JP2006527197A (ja) | p38キナーゼ阻害剤組成物及びその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20141223 |
|
MKEX | Expiry |
Effective date: 20141223 |